Work

HSD3B1 and overall survival (OS) in high-risk non-metastatic (M0) and metastatic (M1) prostate cancer starting androgen deprivation therapy (ADT) in the enzalutamide (ENZ) and abiraterone acetate plus prednisolone (AAP) STAMPEDE phase 3 trial.

Year: 2025

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.5_suppl.234

Authors: Nima Sharifi, Mahaz Kayani, Laura Murphy, Robert Diaz, Emily Grist, Zsofia Kote-Jarai, Ros A. Eeles, Gianmarco Leone, Noel W Clarke, Mahesh K. B. Parmar, Louise C. Brown, Nicholas David James, Gerhardt Attard

Institutions: University of Miami, Sylvester Comprehensive Cancer Center, University College London, Medical Research Council, Institute of Cancer Research, Salford Royal NHS Foundation Trust, The Christie NHS Foundation Trust, MRC Clinical Trials Unit at UCL, Royal Marsden NHS Foundation Trust, Royal Marsden Hospital

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4407678170

Cites:

Cited by:

Related to: 10